ABSTRACT
The authors treated with Biostim (Roussel Uclaf Co., France) 20 children aged 3 to 15 years with relapsing and chronic diseases of the respiratory system. A favourable clinical effect was observed in 45% and improvement in 40% of the patients. In the investigated immunological indicators the response to treatment Biostim was manifested in the antibody immunity by a reduction of IgE values (P < 0.01) and of IgM (P < 0.05). As to cellular immunity, there was a significant increase of the phagocytic activity (P < 0.05). The tolerance of the preparation was very good.
Subject(s)
Bacterial Proteins/therapeutic use , Respiratory Tract Diseases/therapy , Adjuvants, Immunologic/therapeutic use , Adolescent , Child , Child, Preschool , Humans , Recurrence , Respiratory Tract Diseases/immunologyABSTRACT
The authors treated on account of relapsing respiratory diseases 95 children with Broncho-vaxom (Lab. ltd. Meyrin, Geneva) and 75 children with bacterial vaccine prepared with regard to the microbiological examination. Restoration or improvement of the clinical condition was achieved in 80% of the patients. No side-effects were observed during treatment. As to investigated immunological indicators they recorded after treatment a significant reduction of IgM (P less than 0.001), IgA (P less than 0.01), SIgA in saliva (P less than 0.01), values of the nitroblue tetrazolium test (P less than 0.01) and (P less than 0.05). The assembled data revealed that bacterial vaccines are useful as immunomodulating preparations.
